Literature DB >> 23297055

The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy.

Shi Chen1, Xing-Yu Feng, Yuan-Fang Li, Bai-Wei Zhao, Zhi-Wei Zhou, Ying-Bo Chen.   

Abstract

AIM: To investigate the clinical significance of the postoperative serum carcinoembryonic antigen (CEA) levels in gastric cancer patients who underwent D2 radical gastrectomy and to identify the prognostic factors for patients with marginally elevated postoperative CEA levels.
METHODS: We performed a retrospective study of 480 patients who were histologically diagnosed with gastric cancer and who underwent D2 radical surgery at the Sun Yat-sen University Cancer Center between January 2004 and December 2009. The follow-up lasted until June 2011. Chi-squared tests and Kaplan-Meier methods were employed to compare the adverse events and prognoses.
RESULTS: In this group of gastric cancer patients, the postoperative serum CEA level (P = 0.002) was an independent prognostic factor; the same was true for the histological T and N staging (P < 0.001 and P = 0.045, respectively). In the group of marginally elevated postoperative CEA level gastric cancer patients, univariate analysis demonstrated that tumor position (P = 0.042); histological grade (P = 0.002); and Boarrmann type (P = 0.003) were significant prognostic factors. Multivariate analysis showed that the tumor position (P = 0.003) and histological grade (P = 0.007) were independent prognostic factors for these patients.
CONCLUSION: Our study showed that patients with normal postoperative CEA levels have a better prognosis. Furthermore, for marginally elevated postoperative CEA level gastric cancer patients, the tumor position and histological grade were two important factors for predicting the prognosis and the need for aggressive therapy.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23297055     DOI: 10.1002/jso.23300

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  At which stage of gastric cancer progression do levels of carcinoembryonic antigen and carbohydrate antigen 19-9 increase? Application in advanced gastric cancer treatment.

Authors:  Eui Soo Han; Han Hong Lee; Jun Suh Lee; Kyo Young Song; Cho Hyun Park; Hae Myung Jeon
Journal:  J Gastric Cancer       Date:  2014-06-30       Impact factor: 3.720

2.  Monitoring of peri-distal gastrectomy carbohydrate antigen 19-9 level in gastric juice and its significance.

Authors:  A-Man Xu; Lei Huang; Wen-Xiu Han; Zhi-Jian Wei
Journal:  Int J Clin Exp Med       Date:  2014-01-15

3.  Detection of perioperative cancer antigen 72-4 in gastric juice pre- and post-distal gastrectomy and its significances.

Authors:  Lei Huang; Aman Xu; Tuanjie Li; Wenxiu Han; Shanshan Wu; Yangyi Wang
Journal:  Med Oncol       Date:  2013-07-03       Impact factor: 3.064

4.  The predictive value of the preoperative C-reactive protein-albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data.

Authors:  Bin-Bin Xu; Jun Lu; Zhi-Fang Zheng; Jian-Wei Xie; Jia-Bin Wang; Jian-Xian Lin; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ze-Ning Huang; Ju-Li Lin; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  Gastric Cancer       Date:  2019-02-09       Impact factor: 7.701

5.  Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies.

Authors:  Lin Yang; Sheng Wei; Rongxian Zhao; Yingxing Wu; Hong Qiu; Huihua Xiong
Journal:  Sci Rep       Date:  2016-06-29       Impact factor: 4.379

6.  Prognostic values of normal preoperative serum cancer markers for gastric cancer.

Authors:  Fan Feng; Li Sun; Zhen Liu; Shushang Liu; Gaozan Zheng; Guanghui Xu; Man Guo; Xiao Lian; Daiming Fan; Hongwei Zhang
Journal:  Oncotarget       Date:  2016-09-06

7.  Perioperative CRP: A novel inflammation-based classification in gastric cancer for recurrence and chemotherapy benefit.

Authors:  Jun Lu; Bin-Bin Xu; Zhen Xue; Jian-Wei Xie; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  Cancer Med       Date:  2020-12-03       Impact factor: 4.452

Review 8.  Classic tumor markers in gastric cancer. Current standards and limitations.

Authors:  Călin Căinap; Viorica Nagy; Alexandra Gherman; Sanziana Cetean; Istvan Laszlo; Anne-Marie Constantin; Simona Căinap
Journal:  Clujul Med       Date:  2015-04-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.